MapLight's Phase 2 split results trigger big stock drop as twice-daily dose shines
MapLight Therapeutics’ stock slid over 60% after Phase 2 results for its schizophrenia candidate ML-007C-MA showed a clear benefit for the twice-daily 210/3 mg dose on PANSS, while the once-daily 330/6 mg dose did not reach statistical significance; the company will pursue further analyses to decide next steps for the other dose. The treatment was generally well-tolerated, with exploratory signals of cognitive benefit, and the company highlighted potential upside in Alzheimer's psychosis and competitive positioning versus BMS’s Cobenfy.